Journal of Cancer Science and Research
Open Access

Kawakami S

Publications

• Research Article
  Prophylactic Anti-allergic Drug Administration to Prevent Docetaxel and Cyclophosphamide-induced Skin Toxicity: Sub-analysis of a Multiinstitution Neoadjuvant Chemotherapy Trial in Primary Breast Cancer Patients
  Author(s): Nakatsukasa K*, Koyama H, Ouchi Y, Sakaguchi K, Matsuda T, Fujiwara I, Kadotani Y, Kawakami S, Konishi E and Taguchi T Nakatsukasa K*, Koyama H, Ouchi Y, Sakaguchi K, Matsuda T, Fujiwara I, Kadotani Y, Kawakami S, Konishi E and Taguchi T
  
  Background: TC (a combination of 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide q3W) is used for neoadjuvant/adjuvant chemotherapy in the treatment of primary breast cancer. We have recently encountered many cases of skin eruption related to TC therapy, but the effectiveness of prophylactically using anti-allergic drugs remains unclear. In this study, we aimed to determine whether the prophylactic use of anti-allergic drugs could be beneficial for the prevention of TC-related skin toxicity. Methods: We retrospectively investigated the incidence of skin eruption related to TC or a combination of docetaxel, cyclophosphamide, and trastuzumab (HER-TC) among patients with or without prophylactic anti-allergic drug administration by performing a sub-analysis of data from a previous clinical trial. For neoadjuvant chemotherapy (NAC), four cycles of.. View More»
  DOI: 10.4172/2576-1447.1000111

  Abstract PDF

Relevant Topics